EMBC Embecta Corp.
Price Chart
Executive Summary
Embecta Corp. (EMBC) announced a definitive agreement to acquire UK-based Owen Mumford Holdings Limited, a medical device and drug-delivery innovator, for up to £150 million. The deal includes an upfront cash payment of £100 million and up to £50 million in performance-based earnouts tied to sales of the Aidaptus® auto-injector platform. The acquisition expands Embecta's drug delivery capabilities and global footprint, supporting its strategic shift into broader chronic care markets.
Key Financial Metrics
Actionable Insight
Traders should monitor Embecta’s Q2 2026 earnings call on May 5, 2026, for further details on integration plans, financing assumptions, and long-term guidance. The earnout structure aligns with execution risk, but leverage increase may pressure near-term sentiment. Long-term upside hinges on global commercialization of Aidaptus® and cross-selling opportunities.
Key Facts
- Embecta is acquiring Owen Mumford for up to £150 million ($189M at ~1.26 USD/GBP), with £100M upfront and £50M in performance-based earnouts.
- Owen Mumford generated £69.4M in net revenue in FY2025, with 80% from the U.S. and UK.
- The deal is expected to close in Embecta’s fiscal Q3 2026, subject to regulatory approvals.
- Acquisition is expected to be accretive to adjusted operating income and net income beyond fiscal 2027, with high-single-digit ROIC by year four.
- Financed via borrowings under Embecta’s revolving credit facility.
- Owen Mumford brings the Aidaptus® next-gen auto-injector platform and complementary manufacturing and commercial capabilities.
Financial Impact
Upfront deal value of $126 million (based on £100M at 1.26 USD/GBP), representing ~24% of Embecta's current market cap. Owen Mumford contributed ~$87.4M in annual revenue (at same exchange rate), adding ~17% to Embecta's current revenue base assuming no overlap.
Risk Factors
- Execution risk in integrating Owen Mumford and scaling the Aidaptus® platform globally.
- Dilution to adjusted net income in fiscal 2027 due to acquisition costs and financing.
- Dependence on future sales performance for full earnout realization.
- Regulatory delays or conditions that could push back closing.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258815 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
26d ago
|
8-K
| $3.14 $3.32 | ▲ +5.73% | ▲ +4.77% | $3.26 (+3.66%) |
|
May 5, 2026
5w ago
|
8-K
| $3.90 $3.36 | ▲ +13.85% | ▲ +15.83% | $3.26 (+16.54%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $9.21 $8.89 | ▼ −3.47% | ▼ −3.53% | $3.26 (−64.66%) |
|
Mar 20, 2026
11w ago
|
8-K
| $8.89 $8.57 | ▼ −3.60% | ▼ −1.45% | $3.26 (−63.39%) |
|
Mar 19, 2026
11w ago
|
Press Release
| $9.12 $8.87 | ▼ −2.74% | ▼ −0.53% | $3.26 (−64.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access